Concepedia

Admet-guided Potency Optimization

ADMET-Guided Potency Optimization is a medicinal chemistry strategy that integrates absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties as early-stage constraints to guide the enhancement of a drug candidate's pharmacological potency while maintaining favorable safety and pharmacokinetic profiles.

14

Publications

1.5K

Citations

140

Authors

37

Institutions

Publications per year

2017–2026

3

Parents

Publications

14

ADMET—turning chemicals into drugs

John Hodgson · Nature Biotechnology · 2001 · 427 citations

, , +11

ADME evaluation in drug discovery

Tingjun Hou, Xiaojie Xu · Journal of Molecular Modeling · 2002 · 257 citations

, , +9

ADME/PK as part of a rational approach to drug discovery

Peter Eddershaw, Alan Beresford, Martin K. Bayliss · Drug Discovery Today · 2000 · 242 citations

, , +11

Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING

Tony Siu, Michael D. Altman, Gretchen A. Baltus et al. · ACS Medicinal Chemistry Letters · 2018 · 172 citations · Full text

, , +14

Potency optimization of Huwentoxin-IV on hNav1.7: A neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena

Jefferson D. Revell, Per-Eric Lund, John E. Linley et al. · Peptides · 2013 · 75 citations

, , +11

1–5 of 14

Authors

140

  1. MJ
    Michael J. Munchhof

    Pfizer (United States), United States

    1 publications · 31 citations

    1

    h-index

  2. CM
    Clare M. Jones

    Mount Vernon Hospital, United Kingdom

    1 publications · 75 citations

    1

    h-index

  3. JM
    Joaquim Matéo

    Hôpital Lariboisière, France

    1 publications · 54 citations

    1

    h-index

  4. GK
    Gottfried K. Schroeder

    University of North Carolina at Chapel Hill, United States

    1 publications · 172 citations

    1

    h-index

  5. SM
    Sandra M. Jennings

    Pfizer (United States), United States

    1 publications · 31 citations

    1

    h-index

1–5 of 140

Institutions

37

  1. Bristol-Myers Squibb (United States)

    New York, United States

    2 h-index

    2 publications

    67 citations

  2. Pfizer (United States)

    New York, United States

    2 h-index

    32 publications

    990 citations

  3. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    2 h-index

    2 publications

    104 citations

  4. Roche (Switzerland)

    Basel, Switzerland

    1 h-index

    2 publications

    58 citations

  5. The Nature Conservancy

    Arlington, United States

    1 h-index

    1 publications

    427 citations

  6. Medical University of Warsaw

    Warsaw, Poland

    1 h-index

    2 publications

    30 citations

  7. Santhera Pharmaceuticals (Switzerland)

    Liestal, Switzerland

    1 h-index

    12 publications

    276 citations

  8. Janssen (Belgium)

    Beerse, Belgium

    1 h-index

    1 publications

    29 citations

1–8 of 37

Venues

  1. Bioorganic & Medicinal Chemistry Letters

    2 publications · 67 citations

    2

    h-index

  2. MedChemComm

    1 publications · 31 citations

    1

    h-index

  3. Peptides

    1 publications · 75 citations

    1

    h-index

  4. Drug Discovery Today Therapeutic Strategies

    1 publications · 12 citations

    1

    h-index

  5. Journal of Medicinal Chemistry

    1 publications · 38 citations

    1

    h-index

1–5